RxDoctor Payments Data

Jonathan Yager, MD

Cardiovascular Disease · Fairfax, VANPI 1043302615

Payments from drug & device makers

$1,073in general payments, 2019–2025

Across 36 payments — averaging $29.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$328
  • Medtronic$194
  • Abbott$145
  • Amgen$87
  • Medicomp Inc$74
  • E.r. Squibb & Sons, L.L.C.$71
  • plus $175 from 8 others

What the payments were for

  • Food & beverage$1,073100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis13$328
Medtronic(2 entities)3$194
Abbott1$145
Amgen4$87
Medicomp Inc1$74
E.r. Squibb & Sons, L.L.C.4$71
Amarin Pharma, Inc.2$36
Esperion Therapeutics, Inc.2$34
Novo Nordisk1$25
Boston Scientific1$20
Merck1$17
Astellas Pharma US Inc1$17
Johnson & Johnson1$13
Infobionic, Inc1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,073 in reported general payments places this provider in the 40th percentile of 548 cardiovascular disease providers in Virginia.

See all cardiovascular disease providers in Virginia

Medicare billing

Part B allowed, 2024
$946,216
Medicare patients
2,277
Services billed
8,669

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban482$665,731
EntrestoSacubitril/Valsartan113$157,555
XareltoRivaroxaban81$110,047
Repatha SureclickEvolocumab91$98,861
JardianceEmpagliflozin28$37,872
NexlizetBempedoic Acid/Ezetimibe13$15,417
MultaqDronedarone Hcl13$11,274
Dabigatran EtexilateDabigatran Etexilate Mesylate29$10,682
Metoprolol Succinate604$9,460
Nebivolol Hcl135$8,938
Atorvastatin Calcium690$7,864
NexletolBempedoic Acid12$7,807
Rosuvastatin Calcium402$7,563
Ezetimibe227$6,785
BystolicNebivolol Hcl12$6,542

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$328$157,555113 claims
Johnson & JohnsonXarelto$13$110,04781 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$34$23,22425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 548 cardiovascular disease providers in Virginia.

Other cardiovascular disease in Fairfax

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →